Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 3, 1999, Pages 257-262

  Alexopoulos, K ^a   Kouroussis, C ^b   Androulakis, N ^b   Papadakis, E ^c   Vaslamatzis, M ^a   Kakolyris, S ^b   Samelis, G ^d   Patila, E ^a   Vossos, A ^c   Samantas, E ^e   Georgoulias, V ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

^e Agii Anargyri Cancer Center   (Greece)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Second line treatment

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; PLATINUM;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DEPOLYMERIZATION; ELECTROCARDIOGRAM; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; MICROTUBULE ASSEMBLY; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0032947749     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050892     Document Type: Article

References (27)

1. Aapro M, Pujade-Lauraine E, Lhomme C, et al. (1993) A phase II study of Taxotere in ovarian cancer (abstract). Proc Am Soc Clin Oncol 12: 256
2. Boffetra P, Parkin DM (1994) Cancer in developing countries. CA 44: 81-90
3. Burris S, Eckardt J, Fields S, Rodrignez G, Smith L, Thurman A, et al. (1993) Phase II trials of Taxotere in patients with non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 12: 335
4. Cabral FR (1983) Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 97: 22-29
5. Denis JN, Greene AE, Guenard D, Gueritta-Voegelien F, Mangatal L, Potier P (1998) A highly efficient practical approach to natural taxol. J Am Chem Soc 110: 5917-5919
6. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, et al. (1994) Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12: 1238-1244
7. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soter R, et al. (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645-651
8. Francis AP, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Wooley KJ, et al. (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12: 1232-1237
9. Gandara DR, Vokes E, Green M, et al. (1997) Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial (abstract). Proc Am Soc Clin Oncol 16: 454a
10. Georgoulias V, Kourousis C, Kakolyris S, Androulakis N, Dimopoulos M-A, Papadakis E, et al. (1997) Second-line treatment of advanced non-small-cell lung cancer with paclitaxel and gemcitabine: a preliminary report of an active regimen. Semin Oncol 24 [Suppl 12]: 61-66
11. Gueritte-Voegelein F, Guenard D, Lavella F, Le Goff MT, Mangatal L, Potier P (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992-998
12. Gupta RS (1985) Cross-resistance of vinorelbine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep 69: 515-521
13. Hill BT, Whelan RDH, SheMard SA, McClean S, Hosking LK (1994) Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182
14. Kane SB, Piccart M, Aapro M, Kavanagh J (1995) Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer II A [Suppl 4]: 514-517
15. Kaplan EL, Meier P (1985) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
16. Kavanagh JJ, Kubelka AL, Freedman RS, et al. (1993) A phase II trial of Taxotere in ovarian cancer patients refractory to cisplatin/carboplatin therapy (abstract). Proc Am Soc Clin Oncol 12: 259
17. Kelland LR, Abel G (1992) Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450
18. Kunitoh H, Watanabe K, Onoshie T, Furuse K, Nitani M, Taguchi T (1996) Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14: 1649-1655
19. Mangatal L, Adeline MT, Guenard D, Geuritte-Voegelein F, Potier P (1989) Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogs. Tetrahedron 45: 4177-4190
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
21. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-972
22. Non-Small Cell Lung Cancer Cooperative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients. BJM 311: 899-909
23. Piccart MJ, Verweij J, Kaye SD, et al. (1993) Taxotere: an active new drug for the treatment of advanced ovarian cancer (abstract). Proc Am Soc Clin Oncol 12: 258
24. Reed E (1993) Platinum analogues. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology, 4th edn. Lippincott, Philadelphia, pp 390-400
25. Ringel I, Horwitz SB (1991) Studies with PR56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291
26. Robinet G, Kleisbauer JP, Thomas P, et al. (1997) Phase II of docetaxel (Taxotere) in first-and second-line NSCLC (abstract). Proc Am Soc Clin Oncol 16: 480A
27. Roy SN, Horwitz SB (1985) A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 44: 3856-3863